Étiquette : anxiété

Avec le confinement : beaucoup de syndromes de manque, Benjamin ROLLAND, 19/03/2020

Avec le confinement: beaucoup de syndromes de manque Benjamin ROLLAND https://www.addictolyon.fr/post/avec-le-confinement-beaucoup-de-syndromes-de-manque Addictolyon, 19/03/2020, Mis à jour : il y a 4 jours     Avec le #confinement lié au #COVID19, les trafics de substances semblent s'être fortement réduits. Résultat: en ville, à l'hôpital, en prison, de nombreux syndromes de manque apparaissent. Afin de faciliter la reconnaissance et la prise en charge des syndrome de sevrage chez les patients, voici un petit document explicatif du repérage et du traitement des syndrome de sevrage à catégories importantes de substance: #tabac, #cannabis, et #opioïdes

Lire la suite

Autorisation Temporaire Exceptionnelle d’Utilisation compassionnelle du cannabis médical, Laurent Appel, ASUD, 26 mars 2020

Autorisation Temporaire Exceptionnelle d'Utilisation compassionelle du cannabis médical Laurent Appel (conseil en communication spécialisé en réduction des risques) 06.81.54.10.96 mailto : laurent.appel@asud.org relayé par    www.Principesactifs.org, 26/03/2020   La chaine de soins et de médicament est en tension maximum. Le rôle de chacun est de détecter les failles actuelles et surtout futures pour éviter d'ajouter encore de la tension et faire tout sauter.Le cannabis médical peut jouer un rôle majeur tant comme solution thérapeutique alors que qon manque sera un facteur important de tensions.   D'un point de vue médical, il va manquer aux patients déjà traités clandestinement et surtout au million de patients en automédication. Nous risquons donc avoir [...]

Lire la suite

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential, C. Michael White, 2019

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387   Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]

Lire la suite

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models, Claire J. Foldi et al., 2020

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models Claire J. Foldi, Paul Liknaitzky, Martin Williams, Brian J. Oldfield Frontiers in Neuroscience, 2020 | Volume 14 | Article 43 : 1-8 doi : 10.3389/fnins.2020.00043   Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite

Bibliographie : Cannabidiol (CBD), Docteur Christian SUEUR, GRECC, mars 2020.

Bibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, mars 2020.     voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives    

Lire la suite

Is cannabis an effective treatment for anxiety disorders ?, Anxiety.org, septembre 2019

Is cannabis an effective treatment for anxiety disorders ? https://www.anxiety.org/is-cannabis-an-effective-treatment-for-anxiety-what-research-shows Lindsey Salerno, M.Ed. from Philadelphia College of Osteopathic Medicine Jesse McCann, B.S. from University of Pennsylvania, School of Medicine Shari Lieblich, B.S. from University of Pennsylvania, School of Medicine Jeremy Tyler, Psy.D. from University of Pennsylvania Is cannabis really an effective treatment for anxiety? Research and evidence shows mixed results so learn the facts here and consult a professional. Facts v. Fiction: What the research says What is cannabis (marijuana)? What are common misconceptions? Yes - cannabis can be an effective anxiety treatment - but the opposite is also true Participate in a clinical trial [...]

Lire la suite

Use of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence, Madison Wright et al., 2019

Use of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence Madison Wright, Patricia Di Ciano, and Bruna Brands Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 1-6. Doi : 10.1089/can.2019.0052   Abstract Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as [...]

Lire la suite

Serotoninergic hallucinogens/psychedelics could be promissing treatments for depressive and anxiety disorders in end-stage cancer, Rafael Guimarães dos Santos et al., 2019

Serotoninergic hallucinogens/psychedelics could be promissing treatments for depressive and anxiety disorders in end-stage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321, 1-4. Doi : 10.1186/s12888-019-2288-z   Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, mars 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, mars 2020.   Généralités : 1 - 8 Cannabidiol anxiolytique : 9 - 10 Cannabidiol antipsychotique : 11 - 16 Cannabinoïdes et dépression : 17 – 20 Cannabidiol antidépresseur : 21 - Cannabinoïdes et Sommeil : 22 Cannabinoïdes et addictions : 23 - 26     2e version, décembre 2019....   Cannabinoides et PTSD : cf la Bibliographie : Cannabinoïdes et PTSD https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-ptsd-docteur-christian-sueur-grecc-2019/ Substances psychédéliques et Addictions : cf Bibliographie : Substances psychédéliques et  et traitements des Addictions https://www.grecc.org/publications/bibliographies/bibliographie-substances-psychedeliques-et-cannabinoides-et-traitement-des-addictions-dr-christian-sueur-grecc-octobre-2019/

Lire la suite